脊髓电刺激试验-植入比率:过时指标还是必要标准?
本文讨论脊髓电刺激(SCS)试验-植入比率的价值与局限,指出该比率从2009年Medicare数据的42.5%升至2018年超过63%,2020-2021年随机临床试验报告超过80%-90%,提示仅少数候选者未后续植入。作者主张重新评估该范式,并建议纳入人均试验利用率和取出-植入比率等替代指标。
要点
- SCS试验-植入比率随技术进展显著升高,2009年42.5%,2018年超63%,2020-2021年RCT超80%-90%。
- 该比率可防止过度使用并标准化实践,但与长期结局不一致,需补充人均试验利用率和取出-植入比率。
- 欧洲采用验证性症状筛查工具和直接植入路径替代筛选试验,作为优化SCS利用的策略。
核心结论
- 试验-植入比率仍可作为防止过度使用的保障和标准化工具,但需结合人均试验利用率和取出-植入比率等替代指标综合评估。
研究设计与样本
- 本文为论述性文章,基于美国疼痛医师视角,引用Medicare数据(2009年试验-植入比率42.5%,2018年超过63%)和2020-2021年随机临床试验数据(比率超过80%-90%)进行讨论。
主要发现
- Medicare数据显示试验-植入比率从2009年的42.5%升至2018年的超过63%。
- 2020至2021年随机临床试验报告的试验-植入比率超过80%-90%。
- 试验-植入比率升高提示仅少数SCS候选者未后续植入永久设备。
- 该比率与长期结局缺乏一致性,需替代指标如人均试验利用率和取出-植入比率。
- 欧洲采用验证性症状筛查工具和直接植入路径替代筛选试验。
临床怎么用
- 临床应平衡看待试验-植入比率,不应单独依赖该指标评估SCS患者选择和质量。
- 可参考人均试验利用率和取出-植入比率等补充指标,并关注欧洲直接植入路径的实践经验。
局限性
- 本文为论述性文章,未提供原始研究数据或系统评价,主要基于美国Medicare数据和随机临床试验的引用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The trial-to-implant ratio for spinal cord stimulation (SCS) has long served as a cornerstone metric for optimizing patient selection and cost containment. Historically, screening trials played a pivotal role in identifying non-responders, thereby minimizing unnecessary permanent implantations. The utility of the trial paradigm is supported by Medicare data from 2009, which reported a trial-to-implant ratio of 42.5%. However, advancements in SCS technology have significantly transformed the neuromodulation landscape and have been associated with higher rates of trial success. By 2018, the Medicare data showed trial-to-implant ratios exceeding 63%, with randomized clinical trials from 2020 to 2021 reporting ratios exceeding 80%-90%. These significant increases in trial-to-implant ratios suggest that only a minority of SCS candidates do not undergo a subsequent permanent device implantation. As such, re-evaluation of the trial-to-implant paradigm, from the perspective of practicing pain physicians in the USA, in light of evolving clinical practices and economic pressures, is warranted. This discourse explores the benefits and limitations of the trial-to-implant ratio, emphasizing its role as a safeguard against overutilization and a tool for standardizing clinical practices but weighed against its shortcomings including a lack of alignment with long-term outcomes, underscore the need for alternative metrics that include per capita trial utilization and explant-to-implant ratios. European responses to similar questions have resulted in utilizing validated symptom screening tools and direct-to-implant pathways in lieu of a screening trial altogether as potential strategies to optimize SCS utilization while maintaining cost-effectiveness. As healthcare systems adapt to advancements in neuromodulation, a balanced perspective on trial-to-implant ratios and complementary metrics is essential to ensure equitable access, sustainable outcomes and evidence-based care for the future of SCS therapy.
引用
- Karri J, Sivanesan E, D'Souza RS, et al. Spinal cord stimulation trial-to-implant ratios: relic or requisite? Reg Anesth Pain Med. 2026. PMID: 40055005. doi:10.1136/rapm-2025-106447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。